guest ::
| Home > Articles > Published articles > Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs |
| Home > Articles > Published articles > Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs |
(Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona) (Hospital Clínic i Provincial de Barcelona)
| Date: | 2021 |
| Abstract: | Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). The median overall survival in sorafenib treated patients was significantly different across groups (6. 8 months for e-diarrhoea, 26. 7 months for L-diarrhoea and 13. 3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1. 84 [95%CI 1. 15-2. 95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0. 66 [95%CI 0. 42-1. 03]). The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies. Established knowledge on this subject What are the significant and/or new findings of this study?. |
| Grants: | Ministerio de Economía y Competitividad CM15/00050 Instituto de Salud Carlos III PI19/00222 Instituto de Salud Carlos III PI13/01229 Ministerio de Economía y Competitividad PI15/00145 Instituto de Salud Carlos III PI18/00542 Instituto de Salud Carlos III PI18/00768 Instituto de Salud Carlos III PI18/0358 |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan aquestes es distribueixin sota la mateixa llicència que regula l'obra original i es reconegui l'autoria de l'obra original.  |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Diarrhoea ; Hepatocellular carcinoma ; Resistance ; Sorafenib ; Survival ; Tyrosine kinase inhibitor |
| Published in: | United European Gastroenterology Journal, Vol. 9 (july 2021) , p. 655-661, ISSN 2050-6414 |
